Status:
UNKNOWN
IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment.
Lead Sponsor:
University of Padova
Collaborating Sponsors:
Associazione Italiana per la Ricerca sul Cancro
Azienda Ospedaliera di Padova
Conditions:
Rectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Background The current management on rectal cancer based on TNM staging has some limitations. In locally advanced rectal cancer after neoadjuvant therapy the persistence of a complete response to ther...
Detailed Description
Locally advanced rectal cancer: which treatment after complete response after neoadjuvant therapy? Combined treatment for locally advanced rectal cancer achieves a 5-year overall survival close to90% ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- locally advanced (cT3-4 and/or N+, TNM stage II-III) low and medium rectal cancer (\<11 cm) or low rectum adenocarcinoma cT≤2, at risk for abdominoperineal amputation, undergoing neoadjuvant therapy will be included in the study group.
- Only neoadjuvant therapy protocols including long course radiotherapy (45 Gy) and fluoropyrimidine-based regimens will be included while short radiation therapy of radiation therapy or chemotherapy alone will be excluded
- at least 6 weeks after the end of the neoadjuvant therapy will be included
- Full availability of clinical records at least 1 year of follow up
Exclusion
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
544 Patients enrolled
Trial Details
Trial ID
NCT04917263
Start Date
January 1 2020
End Date
December 31 2024
Last Update
June 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedale Università di Padova
Padua, Italy, 35128